Teva's Generic Bowel Drug Infringes Patent, Allergan Says
The drugmakers say that Teva’s generic linaclotide infringes U.S. Patent Number 9,708,371, issued to Forest Labs in July. Linzess is distributed in the U.S. by Allergan, the suit says.
Teva filed an abbreviated new drug application in October 2016 and recently amended it with an attack on Forest Labs' patent, according to the complaint.
“Teva recently amended the Teva ANDA to include,...
To view the full article, register now.